ALNY: Alnylam Pharmaceuticals Forvard P/E multiplikatori

alnylam.com (ALNY) grafik logotipi

Alnylam Pharmaceuticals (ALNY) RNA dori vositalari sintezini avtomatlashtirish uchun sun'iy intellekt va robototexnikani joriy qilmoqda. Kompaniyaning forward P/E tarixi baholash dinamikasini aks ettiradi, bunda parametr 17.90 ga yetadi. Yuqori moliyaviy chegaralar va patent himoyasi raqobatchilar uchun kirishning qat'iy to'siqlarini yaratadi. Alnylam Pharmaceuticals (ALNY) ning ekologik siyosati standart chiqindilarni yo'q qilish va ofislarida asosiy energiya optimallashtiruvi bilan cheklangan.

alnylam.com - ALNY Narxning kutilayotgan foydaga nisbati (davr: 04.07.2022 - 17.11.2026)

Alnylam (ALNY) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Fundamental baholash:ALNY Alnylam
alnylam.com brendining mahsuloti

Ko'rsatkichning hisoblanishi Alnylam Pharmaceuticals (ALNY) kompaniyasining joriy bozor qiymati va prognoz qilingan sof foyda nisbatiga asoslangan. Ushbu metrika kutilayotgan daromadning bir dollari uchun xarajatni o'lchab, aktivning premium darajasini aniqlaydi. Alnylam Pharmaceuticals (ALNY) uchun ushbu muvozanat vutrisiranning tijorat muvaffaqiyatiga va RNAi pipeline loyihalari ijrosiga bog'liq. Investor kompaniyaning forward P/E metriklasini tahlil qilish orqali qimmat baholanganlik chegaralarini aniqlaydi. Nisbatning pasayishi biznesning jozibadorligi oshganligidan dalolat beradi.

Alnylam Pharmaceuticals raqobatchilari tahlili

Kelajakdagi narxning foydaga nisbati Vertex Pharmaceuticals Inc. (VRTX)|Kelajakdagi narxning foydaga nisbati INSM (Insmed Inc)|Forvard P/E multiplikatori UTHR (unither.com)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati BioMarin (BMRN)|BBIO: Prognoz qilingan narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati bgm.ltd|COGT: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Xeris Biopharma Inc (XERS)|KROS (Keros Therapeutics, Inc.) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ARCT (Arcturus Therapeutics Holdings Inc.)|Prognoz qilingan narxning foydaga nisbati ETON (Eton Pharmaceuticals, Inc.)|KMDA (Kamada Ltd) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona) - Narxning kutilayotgan foydaga nisbati|Mereo BioPharma Group plc - Forvard P/E multiplikatori|PLX - Forvard P/E multiplikatori|PLRX: Forvard P/E multiplikatori|Applied Therapeutics Inc. (APLT) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Rein Therapeutics, Inc.|GELS: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Aytu BioPharma Inc (AYTU)|Prognoz qilingan narxning foydaga nisbati Chemomab Therapeutics Ltd. CMMB|Forvard P/E multiplikatori SRXH (SRx Health Solutions Inc)|Forvard P/E multiplikatori Polyrizon Ltd PLRZ|Aeterna Zentaris - Forvard P/E multiplikatori|Cyclo Therapeutics (CYTH) - Prognoz qilingan narxning foydaga nisbati|Inozyme Pharma, Inc. (INZY) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati reneopharma.com (RPHM)|Kelajakdagi narxning foydaga nisbati COSCIENS Biopharma Inc